PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 10, 2003Circulation1,647 citations

Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure

View Full Paper
ECEugene S. ChungMPMilton PackerKLKim Hung Lo

Structured PICO

Does infliximab improve the clinical condition in patients with moderate-to-severe chronic heart failure?

P
Population
Patients with moderate-to-severe chronic heart failure
I
Intervention
Infliximab (short-term TNFalpha antagonism, including high doses of 10 mg/kg)
C
Comparator
Placebo
O
Outcome
Clinical condition

Short-term use of infliximab does not benefit and may harm patients with moderate-to-severe heart failure, particularly at high doses.

Abstract

Short-term TNFalpha antagonism with infliximab did not improve and high doses (10 mg/kg) adversely affected the clinical condition of patients with moderate-to-severe chronic heart failure.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chung et al. (2003) studied this question.

synapsesocial.com/papers/69d9ea3b0f32475823a3caaahttps://doi.org/10.1161/01.cir.0000077913.60364.d2
Ask AI
Helpful
Bookmark
Share
View Full Paper